BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tian F, Houle SKD, Alsabbagh MW, Wong WWL. Cost-Effectiveness of Tenofovir Alafenamide for Treatment of Chronic Hepatitis B in Canada. Pharmacoeconomics 2020;38:181-92. [PMID: 31691902 DOI: 10.1007/s40273-019-00852-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Lin Y, Lin X, Chen J, Lin Z. Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy.. [DOI: 10.21203/rs.3.rs-2254145/v1] [Reference Citation Analysis]
2 Kim JJ, Alsabbagh W, Wong WWL. Cost Effectiveness of Implementing a Universal Birth Hepatitis B Vaccination Program in Ontario. Pharmacoeconomics 2023. [PMID: 36708500 DOI: 10.1007/s40273-022-01236-5] [Reference Citation Analysis]
3 Tian F, Feld JJ, Feng Z, Sander B, Wong WWL. Feasibility of hepatitis B elimination in high-income countries with ongoing immigration. J Hepatol 2022;77:947-56. [PMID: 35483535 DOI: 10.1016/j.jhep.2022.04.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Prabhu M, Susich MK, Packer CH, Hersh AR, Riley LE, Caughey AB. Universal Hepatitis B Antibody Screening and Vaccination in Pregnancy: A Cost-Effectiveness Analysis. Obstet Gynecol 2022;139:357-67. [PMID: 35115449 DOI: 10.1097/AOG.0000000000004652] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Dilokthornsakul P, Sawangjit R, Tangkijvanich P, Chayanupatkul M, Tanwandee T, Sukeepaisarnjaroen W, Sriuttha P, Permsuwan U. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand. Appl Health Econ Health Policy 2022. [PMID: 35141850 DOI: 10.1007/s40258-022-00719-y] [Reference Citation Analysis]
6 Inada K, Kaneko S, Kurosaki M, Yamashita K, Kirino S, Osawa L, Hayakawa Y, Sekiguchi S, Higuchi M, Takaura K, Maeyashiki C, Tamaki N, Yasui Y, Itakura J, Takahashi Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N. Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. JGH Open 2021;5:1085-91. [PMID: 34584979 DOI: 10.1002/jgh3.12636] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, McNaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Hepatitis B virus (HBV) viral load, liver and renal function in adults treated with tenofovir disoproxil fumarate (TDF) vs. untreated: a retrospective longitudinal UK cohort study. BMC Infect Dis 2021;21:610. [PMID: 34174833 DOI: 10.1186/s12879-021-06226-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang T, Smith DA, Campbell C, Mokaya J, Freeman O, Salih H, Mcnaughton AL, Cripps S, Várnai KA, Noble T, Woods K, Collier J, Jeffery K, Davies J, Barnes E, Matthews PC. Efficacy and safety of tenofovir disoproxil fumarate (TDF) in hepatitis B virus (HBV) monoinfection: longitudinal analysis of a UK cohort.. [DOI: 10.1101/2020.12.11.20247940] [Reference Citation Analysis]
9 Tenefovir alafenamide in chronic hepatitis B: benefits at high cost. PharmacoEcon Outcomes News 2019;841:31-31. [DOI: 10.1007/s40274-019-6383-7] [Reference Citation Analysis]